Immunocore Restructures R&D Leadership as Executive VP Berman Departs
核心洞察
Immunocore (搜索) announced that Dr. David Berman, Executive Vice President of Research and Development, will leave the company on February 27, 2026, to join a large commercial-stage biotech company.
The company will not seek a direct replacement for Dr. Berman and instead will streamline its R&D structure by promoting two existing leaders to Executive Vice President roles.
Dr. Mohammed Dar, current Chief Medical Officer, and Mark Moyer, Head of Regulatory Sciences, will assume expanded oversight of clinical development and regulatory strategies.
Immunocore (搜索) Holdings plc announced a significant restructuring of its research and development leadership, with Dr. David Berman departing his role as Executive Vice President of Research and Development effective February 27, 2026. The commercial-stage biotechnology company will promote two internal leaders to fill the leadership gap rather than seeking an external replacement.
Dr. Berman, who played a crucial role in delivering the Phase 3 trial that led to KIMMTRAK's approval, has accepted a Development Head position at a large commercial-stage biotech company. CEO Bahija Jallal acknowledged his contributions, stating, "David has been instrumental in delivering the Phase 3 trial that has led to the approval of KIMMTRAK, and in positioning our rich pipeline for success including three ongoing Phase 3 trials."
Leadership Promotions and Strategic Restructuring
Immunocore (搜索) will streamline its R&D structure by promoting Dr. Mohammed Dar, the current Chief Medical Officer, and Mark Moyer, Head of Regulatory Sciences, to Executive Vice President roles. Both leaders will assume expanded oversight of clinical development and regulatory strategies across the company's diverse therapeutic portfolio.
Dr. Dar brings extensive experience from his 16-year career at GSK, Medimmune, and AstraZeneca, where he oversaw the development of several FDA-approved drugs including pazopanib, moxetumomab (搜索), and durvalumab. Since joining Immunocore (搜索) in 2019, he has led clinical development and maintained direct oversight of all clinical programs across the company's oncology, infectious disease, and autoimmune portfolios, while advancing KIMMTRAK to regulatory approval.
Mark Moyer, who joined Immunocore (搜索) in 2018, will become EVP, Chief Regulatory and Quality Officer. He led the regulatory strategy for KIMMTRAK, which is now approved in 39 countries. During his over 35 years in the pharmaceutical industry, Moyer has provided global strategic regulatory leadership for drug development, including over 35 Biologics License Applications and Marketing Authorisation Applications for notable drugs such as nivolumab, elotuzumab, ipilimumab, and dasatinib.
Pipeline and Platform Development
Immunocore (搜索) continues to advance its proprietary ImmTAX platform, which develops TCR (搜索) bispecific immunotherapies designed to treat cancer (搜索), autoimmune diseases (搜索), and infectious diseases (搜索). The company's most advanced therapeutic, KIMMTRAK (tebentafusp-tebn (搜索)), has received approval for treating HLA-A*02:01 (搜索)-positive adult patients with unresectable or metastatic uveal melanoma (搜索) in the United States, European Union, Canada, Australia, and the United Kingdom.
The company maintains three ongoing Phase 3 trials as part of its deep pipeline spanning multiple therapeutic areas. Dr. Dar expressed commitment to the company's strategic priorities, stating, "Along with Mark and our talented R&D colleagues, I am firmly committed to delivering our strategic priorities including progressing our ongoing clinical programs, as we continue to bring transformative therapies to patients."
Company Confidence in Transition
CEO Jallal expressed confidence in the leadership transition and the company's ability to maintain momentum. "We are confident in our world-class R&D organization, leadership and ability to deliver on our near-term milestones and long-term vision," she said.
The restructuring reflects Immunocore (搜索)'s strategy to leverage its existing experienced leadership team while maintaining focus on advancing its clinical programs and bringing transformative immunomodulating medicines to patients across multiple disease areas.